Immunomodulator polyinosinic-polycytidylic acid enhances the inhibitory effect of 13-cis-retinoic acid on neuroblastoma through a TLR3-related immunogenic-apoptotic response

Chuang, Hui‐Ching; Lin, Hung‐Yu; Liao, Pei-Lin; Huang, Chao‐Cheng; Lin, Long-Yau; Hsu, Wen Ming; Chuang, Jiin‐Haur

doi:10.1038/s41374-019-0356-0

Cited by 19 publications

(14 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Toll-like receptors (TLRs) are single-pass membrane-spanning receptors that include 13 members, TLR1-13, and play key roles in the innate immune system [ 167 ]. Aberrant regulation of TLRs has been frequently reported to be involved in oncogenesis, such as the participation of TLR3 in neuroblastoma, breast cancer, hepatocellular carcinoma, nasopharyngeal cancer and lung cancer [ 168 ], and the overexpression of TLR4 in lung cancer, neuroblastoma, colorectal cancer and thyroid cancer [ 169 ]. Dimerization of the receptor is a prerequisite for the activation of many receptors to trigger their downstream pathways.…”

Section: Natural Small Molecule Compound Targeting Receptor and Its A...mentioning

confidence: 99%

Small Molecule Compounds of Natural Origin Target Cellular Receptors to Inhibit Cancer Development and Progression

Wang

Zhao

et al. 2022

IJMS

View full text Add to dashboard Cite

Receptors are macromolecules that transmit information regulating cell proliferation, differentiation, migration and apoptosis, play key roles in oncogenic processes and correlate with the prognoses of cancer patients. Thus, targeting receptors to constrain cancer development and progression has gained widespread interest. Small molecule compounds of natural origin have been widely used as drugs or adjuvant chemotherapeutic agents in cancer therapies due to their activities of selectively killing cancer cells, alleviating drug resistance and mitigating side effects. Meanwhile, many natural compounds, including those targeting receptors, are still under laboratory investigation for their anti-cancer activities and mechanisms. In this review, we classify the receptors by their structures and functions, illustrate the natural compounds targeting these receptors and discuss the mechanisms of their anti-cancer activities. We aim to provide primary knowledge of mechanistic regulation and clinical applications of cancer therapies through targeting deregulated receptors.

show abstract

Section: Natural Small Molecule Compound Targeting Receptor and Its A...mentioning

confidence: 99%

Small Molecule Compounds of Natural Origin Target Cellular Receptors to Inhibit Cancer Development and Progression

Wang

Zhao

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…For example, the co-treatment of ATRA and herbimycin A resulted in a marked increase in NB differentiation in vitro [15]. Contrarily, an immunostimulant polyinosinic-polycytidylic acid enhanced anti-proliferative and pro-apoptotic actions of 13-cis RA, decreasing cell viability by 30% and increasing the number of apoptotic cells by 200% compared to 13-cis RA treatment alone [64]. The expressions of apoptotic markers (TLR3, pIRF3, and MAVS-10% increase; apoptotic protein cleaved-PARP-50% increase) were increased in treated SK-N-DZ cells.…”

Section: Other Drugs That Exhibit Synergy With Ramentioning

confidence: 99%

Differentiating Neuroblastoma: A Systematic Review of the Retinoic Acid, Its Derivatives, and Synergistic Interactions

Bayeva¹,

Coll²,

Piskareva

2021

JPM

View full text Add to dashboard Cite

A neuroblastoma (NB) is a solid paediatric tumour arising from undifferentiated neuronal cells. Despite the recent advances in disease management and treatment, it remains one of the leading causes of childhood cancer deaths, thereby necessitating the development of new therapeutic agents and regimens. Retinoic acid (RA), a vitamin A derivative, is a promising agent that can induce differentiation in NB cells. Its isoform, 13-cis RA or isotretinoin, is used in NB therapy; however, its effectiveness is limited to treating a minimal residual disease as maintenance therapy. As such, research focuses on RA derivatives that might increase the anti-NB action or explores the potential synergy between RA and other classes of drugs, such as cellular processes mediators, epigenetic modifiers, and immune modulators. This review summarises the in vitro, in vivo, and clinical data of RA, its derivatives, and synergising compounds, thereby establishing the most promising RA derivatives and combinations of RA for further investigation.

show abstract

“…Of interest, a preclinical combinatorial approach of NP-loaded TLR agonists with other already-approved immunotherapies such as immune checkpoints or EGFR blocking antibodies led to a more significant antitumor immune response and prolonged survival. These results were associated with an increased count of M1 macrophages in the tumor and a better safety profile of the treatments (Paone et al, 2008;Han et al, 2016;Rodell et al, 2018;Buss and Bhatia, 2020;Chuang et al, 2020;Kim et al, 2020;Smith et al, 2020). Notably, some therapeutic approaches even induced an abscopal effect on distant tumors (Buss and Bhatia, 2020).…”

Section: Toll-like Receptors Agonistsmentioning

confidence: 99%

Nanoparticle-Based Therapies for Turning Cold Tumors Hot: How to Treat an Immunosuppressive Tumor Microenvironment

Giustarini

Pavesi

Adriani

2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Nanotechnologies are rapidly increasing their role in immuno-oncology in line with the need for novel therapeutic strategies to treat patients unresponsive to chemotherapies and immunotherapies. The tumor immune microenvironment (TIME) has emerged as critical for tumor classification and patient stratification to design better treatments. Notably, the tumor infiltration of effector T cells plays a crucial role in antitumor responses and has been identified as the primary parameter to define hot, immunosuppressed, excluded, and cold tumors. Organic and inorganic nanoparticles (NPs) have been applied as carriers of new targeted therapies to turn cold or altered (i.e., immunosuppressed or excluded) tumors into more therapeutically responsive hot tumors. This mini-review discusses the significant advances in NP-based approaches to turn immunologically cold tumors into hot ones.

show abstract

Immunomodulator polyinosinic-polycytidylic acid enhances the inhibitory effect of 13-cis-retinoic acid on neuroblastoma through a TLR3-related immunogenic-apoptotic response

Cited by 19 publications

References 46 publications

Small Molecule Compounds of Natural Origin Target Cellular Receptors to Inhibit Cancer Development and Progression

Small Molecule Compounds of Natural Origin Target Cellular Receptors to Inhibit Cancer Development and Progression

Differentiating Neuroblastoma: A Systematic Review of the Retinoic Acid, Its Derivatives, and Synergistic Interactions

Nanoparticle-Based Therapies for Turning Cold Tumors Hot: How to Treat an Immunosuppressive Tumor Microenvironment

Contact Info

Product

Resources

About